MARKSANS vs NEULANDLAB: Stock Comparison
NEULAND LAB is the larger company by market capitalisation. MARKSANS PHARMA shows a lower P/E, a higher dividend yield and lower leverage, while NEULAND LAB shows a higher ROE, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MARKSANS leads 6; NEULANDLAB leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MARKSANS | NEULANDLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MARKSANS | NEULANDLAB |
|---|---|---|
| Live Price | ₹294.45 | ₹18,935 |
| Day Change | -1.24% | -0.21% |
| Volume | 8.18 L | 40,442 |
| 52-Week High | ₹350.95 | ₹24,225 |
| 52-Week Low | ₹155 | ₹11,500 |
| Distance from 52W High | -16.1% | -21.84% |
Valuation
| Metric | MARKSANS | NEULANDLAB |
|---|---|---|
| Market Cap | ₹13,595 Cr | ₹24,263 Cr |
| P/E Ratio | 26.32x | 48.74x |
| P/B Ratio | 4.5x | 12.94x |
| EPS | ₹3.47 | ₹115.1 |
| Book Value | ₹67.36 | ₹1,461.02 |
| Dividend Yield | 0.3% | 0.18% |
Growth
| Metric | MARKSANS | NEULANDLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 20.8% | 136.4% |
| EPS Growth (TTM YoY) | 63.5% | 664.4% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | MARKSANS | NEULANDLAB |
|---|---|---|
| ROE | 18.2% | 19.42% |
| ROCE | 19.33% | 19.02% |
| Net Margin | 14.16% | 17.99% |
| Operating Margin | 29.29% | 25.35% |
| Debt to Equity | 0x | 0.1x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | MARKSANS | NEULANDLAB |
|---|---|---|
| Promoter Holding | 43.87% | 32.26%▼ 0.36 pp |
| FII Holding | 19.06%▲ 1.59 pp | 21.93%▲ 0.85 pp |
| DII Holding | 5.54%▼ 0.65 pp | 16.26%▼ 0.25 pp |
| Public Holding | 31.53%▼ 0.94 pp | 29.55%▼ 0.24 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MARKSANS PHARMA and NEULAND LAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.